

MOLECULAR GENETICS TEST REQUEST FORM

University of North Carolina Hospitals
101 Manning Drive
Molecular Genetics Laboratory, Rm. 1046 Anderson Pav.
Chapel Hill, NC 27514
Phone: (984) 974-1825 Fax: (984) 974-2496
http://labs.unchealthcare.org/
MIM #963, Chart Location: Physician Orders

PATIENT INFORMATION

Full Name (Last, First, M.I.):
UNC Medical Record Number:
NOT a UNC Hospitals Patient? Add'l Information Needed for Registration
Date of Birth:
Patient Address:
City / State / Zip:
Telephone:

Bill Patient's Insurance (Attach copy of both sides of insurance card) Bill Facility

Requested By: NC GENES Date: _____ Facility Name: _____
Phone Number: _____ Facility Address: _____
Fax Number: _____ City / State / Zip: _____

Indication for Testing and Supporting ICD-10 Code(s): _____
Ordering Physician (Print) _____ Signature: _____ Date: _____

SPECIMEN TYPE SUBMITTED:
 Blood (ACD or EDTA tube) Bone Marrow
 Cerebrospinal Fluid (CSF) Other: _____
Date and Time of Collection: _____

PARAFFIN EMBEDDED TISSUE SUBMITTED:
Tissue Type: _____ Case Number: _____
Date of Collection: _____
Archived Specimen Located at:
 UNC Hospitals Surgical Pathology Department
 Other Institution (Provide Facility Information Above)

- AIAT deficiency (*SERPINA1 Z and S*)
- BRCA1 & BRCA2* Mutation Panel (Call laboratory before ordering. Additional Information needed)
- B-cell clonality (*IgH* and *IgK*)
- T-cell clonality (*TRG*)
- BCR/ABL1 p210
- BCR/ABL1 p190
- BCR/ABL1 mutations (*TKI resistance*)
- Connexin panel (includes *GJB2* and *GJB6*)
- CMV from Guthrie Card (*UNC Only*)
- EBV viral load (*Epstein-Barr Virus*)
- Extract and Hold DNA RNA
- FLT3* ITD Only
- FLT3* TKD and ITD Mutation Panel
- Fragile X syndrome (*FMR1*)
- Kidney Genetic Mutation Panel
- Hemochromatosis (*HFE C282Y* and *H63D*)
- JAK2 1849G>T [V617F]*
- MCAD* (Med.-Chain Acyl-CoA Dehydrogenase, *K329E / Y42H*)
- MTRNR1 (1555A>G)*
- Lymphoid Mutation Panel
- Myeloid Mutation Panel - Select Indication:
 AML MDS Myeloproliferative Neoplasm
 With *FLT3* internal tandem duplication (ITD)
- NPM1* Quantitative RNA PCR
- Plavix response genotyping (*CYP2C19*)
- Prader Willi/Angelman syndromes
- Primary ciliary dyskinesia (PCD) (37 gene panel)
- UGT1A1* genotyping
- Factor V Leiden (*FV1691G>A*)
- Prothrombin (Factor II, *20210G>A*)
- DNA fingerprinting (marrow engraftment/chimerism)
 With CD3 Fractionation
- Cystic Fibrosis mutations. Ashkenazi Jewish Descent?
 Carrier Screen Yes No
 Diagnostic/Symptomatic
- Other: EXOME SEQUENCING

- MSI DNA Assay (Microsatellite Instability): 10 unstained sections of tumor tissue 5-10 micron thickness (preferably greater than 70% tumor on the slide) plus 1 "H&E recut" of the same section AND 10 unstained sections of any non-tumor tissue plus 1 "H&E recut" of the same non-tumor tissue (22 slides total)
- MSI DNA Assay with Immunohistochemistry (IHC) staining* (*MLH1, MSH2, MSH6, PMS2*): 15 unstained sections of tumor tissue 5-10 micron thickness (preferably greater than 70% tumor on the slide) plus 1 "H&E recut" of the same section AND 10 unstained sections of any non-tumor tissue plus 1 "H&E recut" of the same non-tumor tissue (27 slides total).
- GastroGenus Panel for Gastric Cancer (Includes Solid Tumor Mutation Panel, *MLH1* methylation, EBV Viral Load): 15 unstained sections of tumor tissue 4 - 5 micron thickness with greater than 20% tumor on the slide plus 1 "H&E recut"
*IHC performed by UNCH Histology Laboratory.

For the following test(s): 10 unstained sections of tumor tissue 4 - 5 micron thickness and 1 "H&E recut" of the same section. (11 total slides). The following tests require greater than 50% tumor:
 IDH1 & IDH2 *TERT* *MLH1* methylation *MGMT*
The following test requires greater than 20% tumor:
 Solid Tumor Mutation Panel (Excluding Glial Neoplasms)

ALK and ROS1 FISH: 4 unstained slides 4-5 micron thickness plus 1 "H&E recut" (5 total slides). These slides must be reviewed for suitability & marked by a pathologist. Signature required from pathologist who marked the relevant regions for testing. See below.
Percentage tumor: _____
Signature / Date: _____
ALK and ROS1 FISH performed by UNCH Cytogenetics Laboratory

Medicare will only pay for services that it determines to be reasonable and necessary under section 1862(a)(1) of the Medicare law. When ordering tests for which Medicare reimbursement will be sought, physicians should order only those individual tests that are necessary for the diagnosis and treatment of a patient, rather than for screening purposes.
Form revised 3-2018